Viracta Therapeutics (NASDAQ:VIRX) Price Target Lowered to $2.00 at Royal Bank of Canada

Viracta Therapeutics (NASDAQ:VIRX) had its price objective reduced by stock analysts at Royal Bank of Canada from $4.00 to $2.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock.

Separately, Leerink Partners lowered shares of Viracta Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $5.00 to $3.00 in a research report on Friday, August 16th.

Viracta Therapeutics Trading Down 4.4 %

VIRX opened at $0.15 on Thursday. The stock has a fifty day moving average price of $0.22 and a 200 day moving average price of $0.43. Viracta Therapeutics has a 1 year low of $0.13 and a 1 year high of $1.31. The stock has a market cap of $5.95 million, a price-to-earnings ratio of -0.14 and a beta of 0.72.

Viracta Therapeutics (NASDAQ:VIRX) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.10. As a group, sell-side analysts forecast that Viracta Therapeutics will post -0.69 earnings per share for the current fiscal year.

Institutional Trading of Viracta Therapeutics

An institutional investor recently bought a new position in Viracta Therapeutics stock. Stonepine Capital Management LLC bought a new position in Viracta Therapeutics, Inc. (NASDAQ:VIRX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned about 1.27% of Viracta Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 31.37% of the company’s stock.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.